2 sonuçlar
Arama Sonuçları
Listeleniyor 1 - 2 / 2
Yayın Strengthening of reinforced concrete beams without transverse reinforcement by using intraply hybrid composites(Elsevier Ltd, 2021-12) Çakır, Ferit; Acar, Volkan; Aydın, Muhammet Raci; Akşar, Bora; Yıldırım, PınarConcrete is currently among the most widely used materials all around the world. The main advantages of concrete include durability, versatility, and high compressive strength, but significant disadvantages include low tensile strength, low shear strength, and low ductility. To eliminate these disadvantages, longitudinal and transverse reinforcements are usually preferred. Steel is widely used as a reinforcement material in the world, but there is still research underway to find alternative materials. In recent decades, composite materials have been used to reinforce concrete instead of steel materials. This study focuses on Intraply Hybrid Composites (IHCs), which are had an important place in the composite industry and examines how these composites affect concrete beams as far as their shear strength is concerned. For this purpose, A length of 2 m RC beams, with no transverse reinforcement (RC2.0), is prepared and then reinforced with three IHCs, Aramid-Carbon (AC2.0), Glass-Aramid (GA2.0) and Carbon-Glass (CG2.0). After U-shape strengthening, the specimens are inspected in four-point bending tests and the effects of the IHCs are investigated on the shear strength of the beams. The experimental results show that there is an increase of 4.36%, 10.62%, and 15.28% in the ultimate load capacity of AC2.0, CG2.0, and GA2.0, respectively, compared to reference specimen, RC2.0. Furthermore, the type of hybrid composite has a direct impact on the failure modes of the RC beams. Consequently, the IHCs can provide a significant contribution to the structural behavior of RC beams.Yayın Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: a living systematic review with meta-analysis(Elsevier B.V., 2025-12) Højlund, Mikkel; Yılmaz Kafalı, Helin; Kırmızı, Begüm; Fusar-Poli, Paolo; Correll, Christoph U.; Cortese, Samuele; Sabé, Michel; Fiedorowicz, Jess; Saraf, Gayatri; Zein, Josephine; Berk, Michael; Husain, Muhammad I.; Rosenblat, Joshua D.; Rubaiyat, Ruby; Corace, Kim; Wong, Stanley; Hatcher, Simon; Kaluzienski, Mark; Yatham, Lakshmi N.; Cipriani, Andrea; Gosling, Corentin J.; Carhart-Harris, Robin; Tanuseputro, Peter; Myran, Daniel T.; Fabiano, Nicholas; Moher, David; Mayo, Leah M.; Nicholls, Stuart G.; White, Tracy; Prisco, Michele De; Radua, Joaquim; Vieta, Eduard; Ladha, Karim S.; Katz, Jay; Veroniki, Areti A.; Solmi, MarcoSerotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in disease-specific symptoms and all-cause discontinuation. Standardized mean differences (SMD) and relative risk (RR) were estimated using random-effects meta-analysis. Risk of bias (RoB) was assessed with Cochrane’s RoB-tool version 2 and certainty of evidence with GRADE. The review is maintained as living systematic review ( https://ebipsyche-database.org/ ). We included 30 RCTs (1480 participants; female=45.8 %; with psychological support=83.3 %; high RoB=83.3 %). In post-traumatic stress disorder (PTSD), MDMA reduced PTSD symptoms compared to any control ( k = 11; SMD=-0.85 [-1.09; -0.60]; I2=0 %; GRADE=low). In major depressive disorder (MDD), psilocybin/ayahuasca/LSD reduced depressive symptoms ( k = 8; SMD=-0.62 [-0.97; -0.28]; I2=55 %; GRADE=very low). In anxiety disorders, both MDMA and serotonergic psychedelics reduced anxiety symptoms (SMDMDMA=-1.18 [-2.04; -0.32]; I2=0 %; k = 2; GRADE=low and SMDserotonergic=-0.88 [-1.70; -0.06]; I2=54 %; k = 5; GRADE=very low). In alcohol use disorder, neither psilocybin nor LSD reduced abstinence rates ( k = 6; RR=1.42 [0.89; 2.26]; I2=7 %; GRADE=very low). In attention-deficit hyperactivity disorder (ADHD), LSD did not reduce ADHD symptoms ( k = 1; SMD=0.22 [-0.32; 0.76]; GRADE=very low). Moderate certainty in evidence was only found for MDMA on PTSD symptoms when compared to placebo. MDMA/serotonergic psychedelics were not associated with higher risk of all-cause discontinuation (RRMDMA=0.74 [0.32; 1.72]; RRserotonergic=0.81 [0.56; 1.15]). Overall, MDMA/serotonergic psychedelics are promising for the treatment of PTSD, MDD, and anxiety disorders with moderate to large effect sizes. Pragmatic trials, long-term, head-to-head trials exploring the role of psychological support, aiming to identify predictors of response, and accounting for expectancy and functional unblinding are needed. Studies addressing these limitations will likely be required for regulatory approval of psychedelic drugs.
